MedTrace Logo

Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer

NCT02065908 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2016-12-08

No results posted yet for this study

Summary

In the proposed project the investigators will asses whether changes in expression of selected circulating microRNAs in serum could comprise a sensitive and specific biomarker of cardiotoxicity in cancer patients treated with anthracyclines based chemotherapy.

Conditions

Sponsors & Collaborators

  • Pomeranian Medical University Szczecin

    collaborator OTHER

  • West Pomeranian Cancer Center

    lead OTHER

Principal Investigators

  • Bartosz Dąbek, MD · West Pomeranian Cancer Center

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-06-30
Completion
2016-12-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02065908 on ClinicalTrials.gov